<DOC>
	<DOCNO>NCT01013818</DOCNO>
	<brief_summary>The purpose study determine HGS1029 safe well tolerated patient relapse refractory lymphoid malignancy .</brief_summary>
	<brief_title>A Study HGS1029 Subjects With Relapsed Refractory Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Confirmed relapsed/refractory lymphoid malignancies Previously treat least 2 therapeutic regimen ECOG performance &lt; 2 . Life expectancy least 3 month Adequate renal function Adequate hematologic status Adequate liver function Transfusion independent Received therapy ( biological drug ) treat cancer within 4 week prior start treatment HGS1029 exhibit persistent clinical evidence cancer treatment toxicity The use systemic corticosteroid within 1 week start treatment HGS1029 Evidence active bacterial , viral fungal infection within 2 week start treatment HGS1029 Known HIV infection Positive hepatitis B surface antigen positive hepatitis C antibody Grade 2 great neuropathy Pregnant female nursing mother Males female agree use effective contraception study least 30 day last dose HGS1029</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>